在功能性消化不良症治疗4周后全面的益处评估和临床决策:多中心,前性设计,现实世界的研究
Tao Bai1, Dan Zhou1, Jie Chen2
1Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Digestive diseases and sciences
|December 2, 2025
概括
八周的 cinitapride 有效地治疗功能性消化不良 (FD),改善缓解率. 在4周的早期反应评估可以指导继续治疗的决策,以获得更好的患者结果.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 功能性消化不良 (FD) 是一种常见的功能性胃肠道疾病.
- 诊断依赖于基于症状的标准.
- 有效的治疗策略对于管理FD症状至关重要.
研究的目的:
- 评估为期8周的青胺治疗FD的疗效.
- 在治疗4周后,以确定最佳的临床决策.
- 为了确定FD患者治疗反应的预测因素.
主要方法:
- 这是一项现实世界,多中心的前性研究,涉及1530名符合罗马规则IV标准的FD患者.
- 患者接受了为期 8 周的 cinitapride 治疗,其中 1,313 人完成了随访.
- 统计分析包括ANCOVA和Cox回归来评估疗效和预测因素.
主要成果:
- 从第4-8周继续服用西尼塔普里德,与停止治疗相比,显著增加了缓解率.
- 年轻的年龄,较低的BMI,高等教育,非PDS亚型,以及维护和按需方案都预测了反应.
- PDS亚型在60岁以下的患者中显示出更大的疗效.
结论:
- 八周的西尼塔普里德显著改善了FD患者的症状缓解.
- 在4周的早期反应评估可以指导个性化治疗的延续.
- 按需使用cinitapride证明了在减少暴露时的良好疗效.
相关概念视频
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
849
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
849
Peptic Ulcer Disease IV: Management
394
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
394
Drugs for Treatment of Constipation-Predominant IBS
664
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
664
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
502
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
502
Gastroesophageal Reflux Disease II: Clinical Features and Management
647
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
647
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
703
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
703


